enVVeno Presents Venous Valve at TCT
enVVeno Medical showcased its investigational enVVe System, a transcatheter replacement venous valve, at the 38th annual TCT Scientific Symposium.
Updated on Nov. 2, 2026 in Stroke
enVVeno Medical, listed on NASDAQ as NVNO, presented its investigational enVVe System at the 38th annual TCT Scientific Symposium. The device is a transcatheter-delivered replacement venous valve designed to restore one-way blood flow in the deep veins of patients with chronic venous insufficiency.
Why it matters
An estimated 3 million people in the U.S. suffer from severe deep venous insufficiency, a condition for which current treatment centers mainly on compression therapy and wound care. The presentation highlights efforts to address the treatment gap for dysfunctional venous valves.
The presentation cites an estimated 3 million U.S. patients with severe deep venous insufficiency, set against a TCT audience of more than 10,000 attendees. No efficacy or safety results for the investigational device were included in the material reported.
The players
enVVeno Medical
A medical device company listed on NASDAQ under the symbol NVNO, developing the enVVe System for deep venous insufficiency.
Rob Berman
Chief Executive Officer of enVVeno Medical who delivered the company's presentation at the symposium.
The details
Rob Berman, chief executive of enVVeno Medical, delivered the presentation titled 'Changing the Treatment Paradigm for Deep Venous Disease: Transcatheter Replacement Venous Valve' during the Innovation in Endovascular Therapies session. The enVVe System is designed to be delivered via catheter rather than through open procedures.
Timeline
November 2, 2026, 11:30 a.m. PT: Rob Berman presents the enVVe System at the TCT session.
Big Picture
The presentation at the TCT Scientific Symposium places enVVeno's replacement venous valve within the endovascular therapies track, which is where interventional cardiology and vascular device developers present investigational technologies to clinicians and investors. It extends the symposium's focus on transcatheter alternatives to surgical treatment.
For people living with chronic venous insufficiency, the device is still investigational and not yet available as a treatment option. Current care continues to rely on compression therapy and wound management while the enVVe System advances through clinical study.
The takeaway
Investigational devices such as the enVVe System move through conference presentations before their results can be judged, so readers should watch for published clinical data before drawing conclusions about effectiveness.
Further reading
Explore more Stroke coverage for context on cardiovascular and vascular treatment research.
Source note: This article includes information reported by Hawaii Telegraph.
